An HLA-A2.1 transgenic rabbit /Cottontail rabbit papillomavirus (CRPV) infection model has been reported previously. In this study, we incorporated online MHCI epitope prediction software and HLA-A2.1 transgenic mouse and rabbit systems together to demonstrate an efficient way to identify and test immunogenicity of two HLA-A2.1 restricted epitopes from CRPVE1 (161-169 LLFRQAHSV and 303-311 MLQEKPFQL). Both epitopes were able to induce specific cytotoxic CD8 T cells in HLA-A2.1 mice and rabbits after peptide and DNA immunization and in vitro stimulation respectively. Using an epitope DNA vaccination method, we achieved partial and complete protection against CRPV DNA challenge by CRPVE1/161-169 and CRPVE1/303-311 respectively in HLA-A2.1 transgenic outbred rabbits. CRPVE1/303-311 also showed strong and specific therapeutic effects in CRPV-infected HLA-A2.1 transgenic outbred rabbits. Interestingly, epitope CRPVE1/303-311 (but not E1/161-169) showed strong protective immunity in non-transgenic EIII/JC inbred (but not outbred) NZW rabbits. Our data demonstrates an efficient way to identify HLA-A2.1 restricted epitopes for the development of prophylactic and therapeutic vaccines.
Introduction
HLA-A2.1 is a common human MHCI molecule among the Caucasian population. Using an HLA-A2.1 transgenic mouse system, investigators have screened and identified HLA-A2.1 restricted epitopes from a variety of pathogens in the past two decades [1] . Online software makes the prediction of a potential HLA-A2.1 restricted epitope possible. Many well characterized epitopes have been tested for therapeutic effects for viral infection or tumor formation in the A2 mouse model [2, 3] . The disadvantage of the HLA-A2.1 mouse model is the limited susceptibility of the mouse to some human pathogens such as HTLV-1 and syphilis. As a result, it is difficult to predict the protective effects of these and other identified epitopes with this model system. In contrast, the rabbit is susceptible to these pathogens and thus provides an excellent host to test the immunogenicity of different targets. Therefore, we established an HLA-A2.1 transgenic rabbit model in an attempt to compensate for the limitations of the HLA-A2.1 transgenic mouse model [4, 5] . Human papillomaviruses are small DNA tumor viruses, some of which induce malignancy in genital, anal, oropharyngeal and also skin tissues. The viruses show species specificity and thus no animal model is available to study HPV infection in vivo [6] . In addition, no mouse papillomavirus model has been reported so far. We used the cottontail rabbit papillomavirus (CRPV) / rabbit model that mimics high-risk HPV infections in the human population [7] [8] [9] . We have found that CRPV genome can be modified extensively without losing the ability to induce papillomas in rabbits [10] . These unique characteristics make it possible to test the specific immunity induced by an HLA-A2.1 restricted epitope DNA vaccine by embedding the corresponding epitope in the CRPV genome [5] .
In previous studies, we used online MHCI epitope prediction software to screen five HLA-A2.1 restricted epitopes from CRPVE1 and to generate a multivalent epitope DNA vaccine [5] . This vaccine provided complete protection against CRPV infection with a single booster immunization [11] . We further observed that two of the five epitopes (CRPVE1/161-169 and CRPVE1/303-311) could stimulate specific CTLs in the HLA-A2.1 transgenic mouse system by direct peptide immunization. In the current study we have shown that these two epitopes provided strong and specific protective immunity against CRPV DNA infection in HLA-A2.1 transgenic rabbits with both outbred and EIII/JC inbred genetic backgrounds. Partial therapeutic immunity was also induced by CRPVE1/303-311 epitope DNA vaccination in the HLA-A2.1 transgenic outbred rabbits. Immunization with the CRPVE1/303-311 peptide failed to stimulate protective immunity in HLA-A2.1 transgenic outbred rabbits, however. Our data demonstrate a direct correlation between these two transgenic animal model systems showing that these systems can be combined to screen and test protective and therapeutic epitope vaccines in vivo.
Material and Methods

Peptide immunization in HLA-A2.1 transgenic mice and rabbits
CRPVE1/161-169 (LLFRQAHSV), CRPVE1/303-311(MLQEKPFQL) and HBV core T helper peptide (TPPAYRPPNAPIL) were synthesized in the core facility of Pennsylvania State University College of Medicine. CRPVE1/161-169 and CRPVE1/303-311 were diluted into 1×PBS buffer (4 mg/ml containing 5% DMSO). HBV core T helper peptide was diluted into 1×PBS buffer (5.6 mg/ml containing 5% DMSO). Each peptide was mixed with HBV core T helper peptide and incomplete Freund's adjuvant (IFA) at a 1:1:2 ratio with a homogenizer until the mixture was emulsified [12] . Each mouse was injected with 50 μl of emulsion on both sides of the base of the tail. Two mice were used for each peptide immunization. The mice were immunized twice with 2-week intervals between injections. Spleens were harvested one week after the booster immunization. HLA-A2.1 transgenic and normal rabbits were immunized with 200 μl of emulsion subcutaneously for 4 times at 2 week intervals. One week after the final booster immunization, the rabbits were challenged with viral DNA on four back sites respectively as described previously [5] .
Tetramer binding assay
After two rounds of in vitro stimulations, the bulk CTLs from HLA-A2.1 transgenic mice or rabbits were labeled with CD8-FITC and then specific PE conjugated tetramers (synthesized by the tetramer core facility of the National Institute of Health). A two-color flow cytometry analysis was used for detecting specific tetramer binding CD8 T cells at the core facility of Pennsylvania State University College of Medicine [13] .
Intracellular cytokine assay
Bulk mouse CTLs were cultured in triplicate wells of a 96-well plate with 1μM peptide (either E1 peptides or a reference peptide HIVGagP17/77-85) and 1μM Brefeldin A at 37 o C for 3-4 hours. The cells were then labeled with FITC conjugated anti-mouse CD8 and PE conjugated anti-mouse interferon gamma and analyzed by two-color flow cytometry at the core facility of Pennsylvania State University College of Medicine as described previously [5] .
Chromium release assay
T2 cell cultures were labeled with chromium (300 μCi) overnight before the assay and then pulsed with peptides (CRPVE1/161-169 and CRPVE1/303-311) on the day of assay as target cells. In vitro stimulated mouse or rabbit CTLs were harvested and divided into triplet wells using Effector /Target ( E:T ) ratio as 30:1, 10:1. 3.3:1 and 1:1. T2 pulsed CRPVE1/161-169 and T2 pulsed CRPVE1/303-311 were used as negative controls for mice and rabbits immunized with CRPVE1/303-311 and CRPVE1/161-169 respectively. Target cells were cultured with the CTLs at 37 o C for 4 hours. Supernatant from target cells cultured alone and target cells lysed with 5%SDS were counted as minimum and maximum release respectively. The chromium release was counted by a Gamma-counter and the specific killing was calculated using standard formula.
HLA-A2.1 restricted epitope DNA vaccines and vaccination in rabbits
HLA-A2.1 transgenic and non-transgenic rabbits were maintained in the animal facilities of the Pennsylvania State University College of Medicine. All animal care and handling procedures were approved by the Institutional Animal Care and Use Committee of the Pennsylvania State University College of Medicine. HLA-A2.1 transgenic rabbits with outbred genetic background and EIII/JC inbred genetic background were used.
CRPVE1/161-169 and CRPVE1/303-311 epitope DNA vaccines were designed as described previously [5] . An ubiquitin only (Ub3) or HPV16E7/82-90 epitope DNA vaccine was used as control for protective studies. Animals were immunized with CRPVE1/161-169, CRPVE1/303-311and a control DNA vaccine using the same strategy as described previously [5] . In brief, the epitope DNA vaccines were purified with the QIAGEN MaxiPrep kit and adjusted to final concentration of 1μg/1μl in 1× TE buffer and then precipitated onto 1.6μm-diameter gold micro particles at a ratio of 1μg of DNA/0.5mg of gold particles as described by the manufacturer (Bio-Rad, Hercules, California) [14] . Inner ear skin sites were shaved and swabbed with 70% ethanol, and then DNA/gold particles were bombarded onto these sites by a gene gun at 400 lb/in 2 [14] . For protective vaccination, groups of rabbits were immunized twice with CRPVE1/161-169, CRPVE1/303-311 or a control DNA vaccine (Ub3 or HPV16E7/82-90) respectively according to our previously published methods [5] . These animals were subsequently challenged with Hershey progressive CRPV DNA (identified as wild type CRPV, wtCRPV) and an E7 codon-modified DNA (identified as coCRPV) at four left and right back sites respectively (5μg construct/ site) at one week after the booster immunization . The rationale for additional challenge with coCRPV genomes was that these genomes grew more rapidly (Manuscript in preparation) and present a greater vaccine challenge for the immunized rabbits.
For therapeutic experiments, rabbits were challenged with wtCRPV DNA and a wtCRPV DNA with E8ATGko mutant (16) at four left and right back sites respectively (5μg construct/ site). The rationale for including the CRPVE8ATGko mutant papillomavirus in this study was that this latter genome produced slow-growing, small papillomas that could represent a smaller tumor burden for the therapeutic vaccine. Four weeks following infection, the rabbits were immunized with CRPVE1/161-169, CRPVE1/303-311 respectively 3 times at three-week intervals.
Viral DNA challenge on rabbits and statistical analysis
New Zealand White (NZW) outbred and EIII/JC inbred rabbits were anesthetized with 40mg/kg Ketamine and 5mg/kg Xylazine. Rabbit back skin was scarified as reported previously [15] . Three days later, rabbits were challenged with viral DNA (5μg DNA/ site). Beginning three weeks after virus or DNA challenge, the rabbits were monitored weekly for papilloma development.
Papilloma size was determined by calculating the cubic root of the product of length × width × height of individual papillomas in millimeters to obtain a geometric mean diameter (GMD). Data were represented as the means (+ SEMs) of the GMDs for each test group. Statistical significance was determined by unpaired t-test comparison (P<0.05 was considered significant). The frequency of sites without papillomas was calculated as the number of sites without papillomas/total challenged sites. Statistical significance was determined by Fisher's Exact Test (P<0.05 was considered significant).
Results
CTL generation in HLA-A2.1 transgenic mouse system
Using a peptide immunization strategy, two HLA-A2.1 transgenic mice (HHD) were immunized with either CRPVE1/161-169 or CRPVE1/303-311 peptide. The spleens were harvested one week after the booster immunization and cultured in vitro with gamma-irradiated peptide-pulsed mouse dendritic cells prepared as described [16] . After two in vitro stimulations, the cultured bulk CTLs from HLA-A2.1 transgenic mice were tested for the generation of specific CD8 T cells using synthesized tetramers. Both peptide-immunized mice showed a significantly increased population of specific tetramer positive CD8 T cells (P<0.05, unpaired student t test, Fig 1A) .
The bulk CTLs were then examined for intracellular interferon gamma (IFN ) levels using the same protocol reported previously [5] . Mice immunized with both peptides (CRPVE1/161-169 and 303-311) showed significantly increased populations of IFN secreting CD8 T cells when compared to control peptides (P<0.05, unpaired student t test, Figure 1B, C) . Significantly more IFN secreting CD8 T cells were generated in restimulated cultures from CRPVE1/303-311 immunized mice when compared with those from CRPVE1/161-169 immunized mice.
Protective immunity by CRPVE1/303-311 and CRPVE1/161-169 vaccination in outbred HLA-A2.1 rabbits against CRPV DNA infection
Next, we wanted to test if these two immunogenic epitopes could stimulate specific protective immunity in HLA-A2.1 transgenic rabbits following CRPV challenge. Because of the successful use of DNA vaccination in our previous studies, we generated two DNA vaccines expressing each of these two epitopes as described previously [5] . Two independent experiments were conducted. After a single booster immunization, the rabbits were challenged with wtCRPV and coCRPV at left and right back sites respectively. Tumor development was monitored weekly until week 12.
Two independent experiments were conducted: In the first experiment, four HLA-A2.1 transgenic rabbits were used for each group (CRPVE1/161-169, CRPVE1/303-311 and Ub3 control group). One rabbit in the CRPVE1/161-169 group died prior to DNA challenge. One out of three rabbits in this group was protected while all four rabbits in CRPVE1/303-311 group were protected from DNA challenge ( Table 1, P=0 .051, P<0.001 vs. control group, fisher's exact test). No rabbits from the Ub3 control group were protected (Table 1) . In a repeat second experiment, five transgenic rabbits were vaccinated with the CRPVE1/161-169 vaccine and one transgenic rabbit vaccinated with CRPVE1/303-311. Four HLA-A2.1 transgenic rabbits were immunized with the HPV16E7/82-90 epitope DNA vaccine as specificity controls. All rabbits immunized with either CRPVE1/161-169 or CRPVE1/303-311 epitope DNA vaccines were completely protected from both wtCRPV and coCRPV DNA infection while no protection was found in the HPV16E7/82-90 epitope DNA vaccine control group. Taken together, both CRPVE1/161-169 and CRPVE1/303-311 epitope DNA vaccines provided partial and complete protective immunity in HLA-A2.1 transgenic rabbits (Table 1, P<0 .05, fisher's Exact Test).
Protective immunity to CRPVE1/303-311 and CRPVE1/161-169 vaccination in EIII/JC inbred HLA-A2.1 rabbits
We also tested the protective immunity of these two epitope DNA vaccines in HLA-A2.1 transgenic rabbits with an EIII/JC inbred genetic background. As expected, strong immunity against both wtCRPV and coCRPV infection was induced by CRPVE1/303-311 and CRPVE1/161-169 immunization although no significant difference in tumor free sites was found (Table 2, P>0.05, fisher's Exact Test). However, significant smaller papillomas were found between epitope vaccinated rabbits and control rabbits infected with both wtCRPV and coCRPV DNA (P<0.05, unpaired student t test, Figure 2A, B) .
Cross reaction was found in normal ( non HLA A 2.1) EIII/JC inbred rabbits but not in normal outbred rabbits vaccinated with E1/303-311 DNA
To investigate whether CRPVE1/303-311 and CRPVE1/161-169 can be additionally presented by the EIII/JC inbred rabbit MHCI, 3 groups of 4 normal EIII/JC inbred rabbits were immunized with CRPVE1/303-311, CRPVE1/161-169 or HPV16E7/82-90 respectively. One week after the final immunization, the rabbits were challenged with wtCRPV and coCRPV at the left and right back sites respectively. The papilloma outgrowth was monitored weekly at 3 weeks following DNA challenge. Rabbits immunized with CRPVE1/303-311 grew significantly smaller papillomas when compared with those immunized with CRPVE1/161-169 and HPV16E7/82-90 ( Figure 3A , B, P<0.05, unpaired student t test). The papilloma size in CRPVE1/161-169 immunized rabbits was comparable to that in the HPV16E7/82-90 epitope DNA immunized rabbits ( Figure 3A , B, P>0.05, unpaired student t test). Therefore, cross-reactivity was found in HLA-A2.1 transgenic EIII/JC inbred rabbits to the CRPVE1/303-311 epitope but not to CRPVE1/161-169. CRPVE1/303-311 vaccine was also tested for protection in normal outbred rabbits. In contrast to complete protection in HLA-A2.1 transgenic outbred rabbits, no protection was found in normal outbred rabbits vaccinated with CRPVE1/303-311. Papilloma size was comparable in these rabbits to papillomas in the HLA-A2.1 transgenic rabbits immunized with HPV16E7/82-90 DNA vaccine (Figure 4 ). These data suggest that the rabbit MHCI allele in the inbred rabbit colony was rare or absent in this cohort of outbred rabbits.
Therapeutic immunity was induced by CRPVE1/303-311 but not by CRPVE1/161-169 DNA vaccine
CRPVE1/303-311 and CRPVE1/161-169 DNA vaccines were also tested for their possible therapeutic effect in HLA-A2.1 transgenic rabbits. Eleven HLA-A2.1 transgenic rabbits and eight normal rabbits with outbred genetic backgrounds were challenged with wtCRPV DNA and a CRPVE8ATGko mutant [18] at left and right back sites. A month following DNA infection, the rabbits were divided into four groups: six HLA-A2.1 transgenic and four normal rabbits were immunized with CRPVE1/303-311 and five HLA-A2.1 transgenic and four normal rabbits were immunized with CRPVE1/161-169 and boosted twice at 3-week intervals. The animals were monitored weekly and papilloma sizes were recorded.
Papillomas induced by wtCRPV DNA on two of the CRPVE1/303-311 epitope vaccinated and one of the CRPVE1/161-169 epitope vaccinated HLA-A2.1 transgenic rabbits became smaller or regressed while those on the other three became larger. The mean papilloma size on this group of rabbits was significantly smaller when compared to that of the other groups ( Figure 5A , P <0.05, unpaired student t test). Similar results were found from CRPVE8ATGko mutant induced papillomas ( Figure 5B , P <0.05, unpaired student t test). Two out of six rabbits were free of papillomas induced by the CRPVE8ATGko genome and one rabbit had three small tumors. The mean papilloma size of CRPVE8ATGko-induced papillomas was smaller when compared to the mean size before the vaccination treatment although these differences were not statistically different ( Figure 5B , P >0.05, unpaired student t test).
In contrast, papillomas induced by wtCRPV and CRPVE8ATGko in normal rabbits immunized with both epitope DNA vaccines grew significantly larger after the therapeutic treatment than those before therapy treatments when compared to pre-therapy mean size ( Figure 5A , B, P <0.05, unpaired student t test).
Discussion
In this report, we incorporated studies using HLA-A2.1 transgenic mice with the CRPV / HLA-A2.1 transgenic rabbit for comparative and complementary analyses and to test for protection in vivo (rabbit model only). Two HLA-A2.1 restricted epitopes predicted by online programs (CRPVE1/161-169 and CRPVE1/303-311) and identified as immunogenic in the HLA-A2.1 transgenic mice, induced strong protective immunity in HLA-A2.1 transgenic rabbits. The HLA-A2.1 transgenic mouse model has the advantage of reduced cost and a large panel of reagents to test the immunogenicity of potential epitopes [2] . However, the mouse model system does not provide an in vivo infection model for papillomaviruses. In contrast, rabbits can be infected with species-specific papillomaviruses as well as several human pathogenic viruses [HTLV-1/2 [19] , EBV-like virus [20] ]and are also susceptible hosts for tuberculosis and syphilis [21] , [22] . We demonstrated here that our transgenic rabbit model system showed good agreement with the mouse model. The HLA-A2.1 transgenic mouse system can thus be used to prescreen the immunogenicity profiles of predicted epitopes for further characterization in our in vivo rabbit model. Most importantly, our recent work demonstrated that the rabbit papillomavirus (CRPV) genome has a high capacity for modification without compromising its ability to induce papillomas in animals [10] . By generating hybrid and mutant genomes that are functional in the rabbits, we can test specific immunity of predicted epitopes for additional pathogens as well as tumor associated antigens when embedded into the CRPV genome.
HLA-A2.1 molecules have been shown to co-localize with rabbit MHCI exclusively on transgenic cell surfaces [4] . HLA-A2.1 also appears to be expressed at equivalent levels to endogenous rabbit MHCI in our studies. Therefore, a possible dual presentation of single epitopes by both the transgene and a rabbit MHCI could complicate interpretation of the results. Indeed, in this study, we found that the more immunogenic epitope CRPVE1/303-311 functioned as a protective epitope in EIII/JC inbred rabbits. EIII/JC inbred rabbits have a unique MHC molecular constitution when compared to that of the outbred rabbits [18, [23] [24] [25] , and unpublished observations). Since no crystal structure exists for rabbit MHCI molecules, and peptide anchor residues for EIII/JC MHCI molecules are uncharacterized, it will be interesting to eventually determine binding motifs of these rabbit MHCI molecules and peptides. We can suggest that EIII/JC MHCI and HLA-A2.1 are not identical as no protections were observed in the non-transgenic EIII/JC rabbits when vaccinated with peptide CRPVE1/161-169, but protection occurred in the transgenic rabbits.
Skin papillomas are usually difficult to resolve and no effective therapeutic vaccine is available to date [9] . It is intriguing that CRPVE1/303-311 showed potential therapeutic effects in HLA-A2.1 transgenic rabbits. Although papillomas on only one of the six rabbits regressed, those on one other rabbit became significantly smaller after the treatment. Interestingly, a stronger therapeutic effect was found in smaller papillomas induced by CRPVE8ATGko when compared with those larger papillomas induced by wtCRPV. This finding is consistent with our previous reports using a multivalent DNA vaccine, in which we achieved much stronger therapeutic effects in HLA-A2.1 transgenic rabbits [11] . Other studies have demonstrated that rabbits vaccinated with multiple early genes achieved the better therapeutic result [26] [27] [28] . Therefore, multivalent epitope vaccines may be a desirable extension of current therapeutic vaccines.
In summary, we have presented here a novel pathway that incorporates online software and both HLA-A2.1 transgenic mouse and rabbit model systems to test the immunogenicity of HLA-A2.1 restricted epitopes in vitro and in vivo. Our results demonstrate high consistency of epitope responsiveness between these two animal models. We anticipate that the combination of these two systems will prove very useful for the development of both protective and therapeutic HPV vaccines [29, 30] . Table 1 Both CRPVE1/161-169 and CRPVE1/303-311 peptide immunized mice generated specific tetramer binding CD8 T cells that secreting intracellular interferon gamma (IFN ) after in vitro culture. The spleen cells harvested from both CRPVE1/161-169 and CRPVE1/303-311 peptide immunized mice were stimulated with corresponding peptide pulsed mouse dendritic cells twice weekly. These bulk CTLs were then tested for A) tetramer binding and B, C) Intracellular IFNr labeling. An significantly increased population of specific CD8 T cells binding to CRPVE1/161-169 and CRPVE1/303-311 tetramer was found in these mice respectively (P<0.05, unpaired student t test) (A). Significantly more IFN secreting CD8 T cells were also found in these two specific epitope (B, C) vaccinated mice to corresponding peptide stimulation when compared with a reference peptide (P<0.05, unpaired student t test). Papilloma outgrowth in HLA-A2.1 transgenic EIII/JC inbred rabbits after CRPVE1/161-169, CRPVE1/303-311 or a control DNA vaccination. Three groups of HLA-A2.1 transgenic EIII/JC inbred rabbits (N=3) immunized with CRPVE1/161-169, CRPVE1/303-311 or a control DNA twice were challenged with wtCRPV and coCRPV at four left and right back sites respectively. Significantly smaller papillomas were found in both E1 epitope DNA vaccinated rabbits when compared with those in control DNA vaccinated rabbits challenged with both wtCRPV DNA (A) and coCRPV DNA (B) (P<0.01 vs. control group, unpaired student t test). Some challenge sites regressed over the time course. No significant difference was found between these two E1 epitope vaccinated rabbits (P>0.05, unpaired student t test). Papilloma outgrowth in normal outbred rabbits after CRPVE1/303-311 and HPV16E7/82-90 epitope DNA vaccination. Three and four normal outbred rabbits immunized with CRPVE1/303-311 and HPV16E7/82-90 epitope DNA vaccine respectively were challenged with wild type CRPV DNA. Although a growth delay occurred in rabbits that immunized with CRPVE1/303-311 before week 7 after viral DNA challenge, no significant difference in papilloma size was found between these two epitope vaccinated rabbits after week 7(P>0.05, unpaired student t test). 
